EIB or not EIB? That is the question.
This editorial comments on the paper of Pedersen et al. focusing, in particular, on the criteria set by the IOC-MC for documenting exercise-induced asthma and exercise-induced bronchoconstriction (and therefore permitting the use of beta-2 adrenergic drugs) in athletes participating in the Beijing Olympic Games.
Bonini
Sergio
S
Second University of Naples, Italian National Research Council, Institute of Neurobiology and Molecular Medicine (CNR-INMM, ARTOV), Rome, Italy. se.bonini@gmail.com
D018663:Adrenergic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000846:Anniversaries and Special Events; D001250:Asthma, Exercise-Induced / Q000188:drug therapy / Q000517:prevention & control*; D002681:China; D003937:Diagnosis, Differential; D004300:Doping in Sports / Q000517:prevention & control; D006801:Humans; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects; D013177:Sports
D018663:Adrenergic Agents; D018343:Receptors, Adrenergic, beta-2